| Literature DB >> 29538508 |
Guilherme Almeida Rosa da Silva1, Heloisa Loureiro de Sá Neves Motta1, Erik Friedrich Alex de Souza1, Pedro Afonso Nogueira Moises Cardoso1, José Henrique Pilotto2, Walter Araujo Eyer-Silva3, Luiz Cláudio Pereira Ribeiro4, Mônica Soares Dos Santos4, Marcelo Costa Velho Mendes de Azevedo1, Jorge Francisco da Cunha Pinto1, Rogerio Neves Motta1, Fernando Raphael de Almeida Ferry3.
Abstract
OBJECTIVES: The increase in HIV transmissibility in non-ulcerative sexually transmitted infection is already well-established. It is estimated that symptomatic carriers of N. gonorrhoeae and C. trachomatis have a relative risk of 4.8-fold and 3.6-fold, respectively, for the sexual acquisition of HIV. This type of evaluation for asymptomatic urethritis is necessary to reinforce strategies to combat HIV transmission. This study aims to assess the prevalence of patients with asymptomatic urethritis among men diagnosed with HIV-1 and determine the risk factors associated with this infection.Entities:
Mesh:
Year: 2018 PMID: 29538508 PMCID: PMC5962100 DOI: 10.1590/S1678-9946201860011
Source DB: PubMed Journal: Rev Inst Med Trop Sao Paulo ISSN: 0036-4665 Impact factor: 1.846
- Descriptive analysis and associations between the group with and without urethritis including treatment variables (N = 115)
| Variables | Frequencies or means ± SD | OR 95%CI | p-value | |||
|---|---|---|---|---|---|---|
|
| ||||||
| Total (N = 115) | No Urethritis (N = 111) | Urethritis (N = 4) | ||||
|
| 44.57 ± 10.9 | 45.04 ± 10.6 | 31.5 ± 15.15 | - | 0.015* | |
|
| ||||||
|
| Single | 86/115 (74.8%) | 83/111 (74.8%) | 3/4 (75%) | - | |
| Married | 23/115 (20%) | 22/111 (19.8%) | 1/4 (25%) | |||
| Divorced | 4/115 (3.5%) | 4/111 (3.7%) | 0/4 (0%) | |||
| Widower | 2/115 (1.7%) | 2/111 (1.8%) | 0/4 (0%) | 0.94 | ||
|
| ||||||
|
| < 6 yrs | 14/115 (12.2%) | 14/111 (12.6%) | 0/4 (0%) | ||
| 6-10 yrs | 18/115 (15.6%) | 16/111 (14.6%) | 2/4 (50%) | |||
| 10-13 yrs | 54/115 (47%) | 53/111 (47.6%) | 1/4 (25%) | |||
| Incompl. graduation | 13/115 (11.3%) | 13/111 (11.7%) | 0/4 (0%) | |||
| Compl. graduation | 16/115 (13.9%) | 15/111 (13.5%) | 1/4 (25%) | 0.77 | ||
|
| ||||||
|
| 10.45 ± 7.42 | 10.67 ± 7.45 | 4.5 ± 2.64 | - | 0.13 | |
|
| ||||||
|
| 4.64 ± 4.13 | 4.7 ± 4.17 | 2.67 ± 1.52 | - | 0.4 | |
|
| ||||||
|
| No | 10/115 (8.7%) | 9/111 (8.1%) | 1/4 (25%) | 0.26 | |
| Yes | 105/115 (91.3%) | 102/111 (91.9%) | 3/4 (75%) | (0.1-2.8) | 0.3 | |
|
| ||||||
|
| No | 94/115 (82.5%) | 90/111 (82%) | 4/4 (100%) | ||
| Yes | 21/115 (17.5%) | 21/111 (18%) | 0/4 (0%) | Undefined | 0.44 | |
|
| ||||||
|
| none | 96/115 (83.3%) | 92/111 (82.8%) | 4/4 (100%) | - | |
| TMS | 6/115 (5.3%) | 6/111 (5.5%) | 0/4 (0%) | |||
| Macrolide+TMS | 13/115 (11.4%) | 13/111 (11.7%) | 0/4 (0%) | 0.36 | ||
|
| ||||||
|
| No | 71/115 (61.7%) | 70/111 (63%) | 1/4 (25%) | 5.1 | |
| Yes | 44/115 (38.3%) | 41/111 (37%) | 3/4 (75%) | (0.5-50.0) | 0.15 | |
|
| ||||||
|
| none | 71/115 (61.7%) | 70/111 (63%) | 1/4 (25%) | - | |
| macrolide | 4/115 (3.4%) | 4/111 (3.6%) | 0/4 (0%) | |||
| TMS | 7/115 (6.1%) | 6/111 (5.5%) | 1/4 (25%) | |||
| penicillin | 18/115 (15.7%) | 16/111 (14.4%) | 2/4 (50%) | |||
| cephalosporins | 5/115 (4.4%) | 5/111 (4.5%) | 0/4 (0%) | |||
| quinolone | 1/115 (0.8%) | 1/111 (0.9%) | 0/4 (0%) | |||
| RIPE | 5/115 (4.4%) | 5/111 (4.5%) | 0/4 (0%) | |||
| aminoglicoside | 1/115 (0.8%) | 1/111 (0.9%) | 0/4 (0%) | |||
| fluconazol | 1/115 (0.8%) | 1/111 (0.9%) | 0/4 (0%) | |||
| multiple | 2/115 (1.9%) | 2/111 (1.8%) | 0/4 (0%) | 0.24 | ||
|
| ||||||
|
| 3.47% | 0% | 100% (CT) | - | ||
OR – odds ratio, 95%CI - confidence interval 95%, SD – standard deviation, RIPE – rifampicin/isoniazide/pirazinamide/ethambutol, Antibiotic prophylaxis correspond to those individuals who were currently using antibiotics with CD4 count bellow 200 (TMS) or 50 cels/mm3 (Macrolide+TMS). *(p<0,05).
Descriptive analysis and associations between the group with and without urethritis including behavior variables (N = 115)
| Variables | Frequencies or means ± SD | OR 95%CI | p-value | |||
|---|---|---|---|---|---|---|
|
| ||||||
| Total (N = 115) | No Urethritis (N = 111) | Urethritis (N = 4) | ||||
|
| Only men | 35/115 (30.4%) | 33/111 (29.7%) | 2/4 (50%) | - | |
| Only women | 44/115 (38.3%) | 42/111 (37.9%) | 2/4 (50%) | |||
| men and women | 36/115 (31.3%) | 36/111 (32.4%) | 0/4 (0%) | 0.18 | ||
|
| ||||||
|
| No | 25/115 (21.7%) | 25/111 (22.5%) | 0/4 (0%) | ||
| Yes | 90/115 (78.3%) | 86/111 (77.5%) | 4/4 (100%) | Undefined | 0.36 | |
|
| ||||||
|
| never | 10/115 (8.7%) | 10/111 (9%) | 0/4 (0%) | - | |
| <50% | 40/115 (34.8%) | 39/111 (35.2%) | 1/4 (25%) | |||
|
| 65/115 (56.5%) | 62/111 (55.9%) | 3/4 (75%) | 0.41 | ||
|
| ||||||
|
| No | 93/115 (80.9%) | 89/111 (80.2%) | 4/4 (100%) | ||
| Yes | 22/115 (19.1%) | 22/111 (19.8%) | 0/4 (0%) | Undefined | 0.42 | |
|
| ||||||
|
| Sexual | 111/115 (96.5%) | 107/111 (96.4%) | 4/4 (100%) | - | |
| Parenteral | 4/115 (3.5%) | 4/111 (3.6%) | 0/4 (0%) | |||
| Vertical | 0/115 (0%) | 0/111 (0%) | 0/4 (0%) | 0.7 | ||
|
| ||||||
|
| No | 105/115 (91.3%) | 101/111 (91%) | 4/4 (100%) | ||
| Yes | 10/115 (9.7%) | 10/111 (9%) | 0/4 (0%) | Undefined | 0.69 | |
|
| ||||||
|
| No | 84/115 (73%) | 81/111 (73%) | 3/4 (75%) | 0.9 | |
| Yes | 31/115 (27%) | 30/111 (27%) | 1/4 (25%) | (0.1-9.0) | 0.7 | |
|
| ||||||
|
| none | 83/115 (73%) | 80/111 (72%) | 3/4 (75%) | - | |
| marijuana | 7/115 (6.1%) | 7/111 (6.6%) | 0/4 (0%) | |||
| marijuana+cocaine | 12/115 (10.4%) | 11/111 (10%) | 1/4 (25%) | |||
| cocaine | 7/115 (6.1%) | 7/111 (6.6%) | 0/4 (0%) | |||
| hashish | 1/115 (0.9%) | 1/111 (0.9%) | 0/4 (0%) | |||
|
| 5 (3.5%) | 5/111 (4.5%) | 0/4 (0%) | |||
| outras | 0/115 (0%) | 0/111 (0%) | 0/4 (0%) | 0.89 | ||
|
| ||||||
|
| 499 ± 311 | 494 ± 311 | 640 ± 318 | - | 0.35 | |
|
| ||||||
|
| undetectable | 81/115 (70.5%) | 79/111 (71.2%) | 2/4 (50%) | ||
| detectable | 34/115 (29.5%) | 32/111 (28.8%) | 2/4 (50%) | 0.33 | ||
|
| ||||||
|
| 100719 ± 213372 | 106584 ± 219028 | 9814 ± 9318 | 0.54 | ||
|
| ||||||
|
| 3.47% | 0% | 100% (CT) | - | ||
OR – odds ratio, 95%CI - confidence interval 95%, SD – standard deviation. *(p<0,05).
Statistically significant associations between continuous variables (N = 115)
| Variable | Result |
|---|---|
| Age x Time of use of ARV | β = positive, R2 = 0.082 p<0.01 |
| Time since diagnosis x Time of use of ARV | β = positive, R2 = 0.231 p<0.01 |
| Time of use of ARV x CD4+ | β = positive, R2 = 0.073 p<0.01 |
| CD4+ x detectable viral load | β = negative, R2 = 0.2 p<0.01 |
ARV – antirretroviral, β – angular coefficient, R2 - determination coefficient.
- Statistically significant associations between continuous and categorical variables (N = 115)
| Continuous variable | Categorical variable (±SD) | Result | |
|---|---|---|---|
|
| |||
| No Condom use | Condom use | ||
| Age (years) | 53.6 ± 7.42 | 41.2 ± 11.18 | p = 0.03 |
| Condom use < 50% | Condom use | ||
|
| |||
| Age (years) | 47.78 ± 9.21 | 41.2 ± 11.18 | P = 0.04 |
| ARV use (yes) | ARV use (no) | ||
|
| |||
| Time since diagnosis (years) | 11.06 ± 7.37 | 3.44 ± 3.5 | p < 0.01 |
| alcoholism (yes) | alcoholism (no) | ||
|
| |||
| Time since diagnosis (years) | 16.5 ± 8.86 | 9.86 + 7.04 | p < 0.01 |
| Detectable viral load | undetectable viral load | ||
|
| |||
| Time of use of ARV | 4.44 ± 5.07 | 4.81 ± 3.82 | p < 0.01 |
| ARV (yes) | ARV (no) | ||
|
| |||
| CD4+ | 489.76 ± 299.99 | 601.1 ± 419 | p = 0.015 |
| circuncision (sim) | circuncision (no) | ||
|
| |||
| Viral load (detectables) | 7569 ± 15604 | 130527 ± 238358 | p < 0.01 |
| Illicit drugs (yes) | Illicit drugs (no) | ||
|
| |||
| Viral load (detectables) | 42733 ± 86483 | 125930 ± 246920 | p = 0.02 |
DP – standard deviation, ARV – antirretroviral.
- Statistically significant associations between categorical variables (N = 115)
| Variable | Result | |
|---|---|---|
| single | Sex with men | OR = 11.9 (95%CI: 4.25-33). p<0.01 |
| single | Condom use ≥ 50% | OR = 3.4 (95%CI: 1.39-8.15). p<0.01 |
| ARV use | Detectable viral load | OR = 0.1 (95%CI: 0.01-0.4). p<0.01 |
| Prophylaxis for opportunistic infections | Detectable viral load | OR = 4.7 (95%CI: 1.62-13.6). p<0.01 |
| Parenteral exposure | alcoholism | OR = 12.8 (95%CI: 1.59-103) p<0.01 |
OR – odds ratio (confidence interval), ARV - antiretroviral